A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma
- PMID: 28042533
- PMCID: PMC5086327
- DOI: 10.22074/cellj.2016.4715
A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma
Abstract
Approximately 5-10% of all thyroid cancers are medullary thyroid carcinomas (MTC). MTC is mainly sporadic in nature, but 20-30% of cases are hereditary. Genetic testing for hereditary MTC is very important for the patient and his family, but the patients must be receiving appropriate genetic counseling. About 98% of patients with hereditary MTC have germline mutations in exons 10, 11, 13, 14, 15, 16 and intron 16 of the REarrangement during transfection (RET) proto-oncogene, but the etiology of the more frequent sporadic form of MTC (sMTC) is not well understood. Recently, it has been reported that apparently sporadic MTC may involve point mutations in BRAF and RAS genes, with an overall prevalence of almost 10%. Also alteration and abnormal expression of miRNA has been described in MTC. In this review, we attempted to mention some mutations and molecular changes in sporadic and hereditary MTC pathogenesis.
Keywords: Medullary Thyroid Carcinoma; RET Proto-Oncogene; miRNA.
Figures
References
-
- DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94(8):662–669. - PubMed
-
- Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539–547. - PubMed
-
- Griebeler ML, Gharib H, Thomson GB. Medullary thyroid carcinoma. Endocr Pract. 2013;19(4):703–711. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials